This study shows that combined treatment with EMP, a SGLT2 inhibitor that lowers hyperglycemia and Alda-1, an ALDH2 activator, improved exercise tolerance and diastolic function better than EMP alone in a mouse model of HFpEF associated with diabetes. This evidence concerns the gene SLC5A2 and diabetes mellitus.